Mechanisms of coxsackievirus B5 mediated beta-cell death depend on the multiplicity of infection.
Coxsackievirus infections may trigger and accelerate pancreatic beta-cell death, leading to type I diabetes. Unrestricted coxsackievirus B5 replication in cultured beta-cells inoculated with high multiplicity leads to rapid lytic cell death. Evidence from other virus-host cell systems indicates that host cell responses to infection may depend on the multiplicity of infection (MOI). Thus, the aim of this study was to compare the mechanisms of beta-cell death during high versus low multiplicity of coxsackievirus B5 infection. Cultures of highly differentiated mouse insulinoma cells and primary adult human islets were infected with coxsackievirus B5 at multiplicities of >1,000 or <0.5 TCID50 per cell. The results of nuclear morphology and viability stainings, TUNEL staining and electrophoretic DNA fragmentation analysis showed high multiplicity infection to predominantly induce necrosis and transient apoptosis. In low multiplicity culture, however, necrosis was only moderately induced and apoptosis increased steadily with time. This was best demonstrated by a tenfold higher apoptosis/necrosis ratio than after high multiplicity inoculation. Expression of gamma-glutamyl cysteine synthetase increased in both infective cultures but the level of intracellular glutathione permanently depleted only at high multiplicity and recovered fully at low multiplicity. Thus, apoptosis represents an important mechanism of beta-cell death after low multiplicity of coxsackievirus B5 infection. This process is associated with maintenance of a physiological intracellular glutathione profile differing dramatically from the high multiplicity infection during which necrosis dominates and intracellular thiol balance deteriorates. These data suggest that the pattern and mechanisms of coxsackievirus B5 infection induced beta-cell death depend on the MOI.
Biomedicum Helsinki, Program of Developmental and Reproductive Biology, University of Helsinki, Helsinki, Finland. suvi.rasilainen@helsinki.fi
Suvi
S
Rasilainen
Petri
P
Ylipaasto
Merja
M
Roivainen
Risto
R
Lapatto
Tapani
T
Hovi
Timo
T
Otonkoski
D000818:Animals; D017209:Apoptosis; D001562:Benzimidazoles / Q000378:metabolism; D016923:Cell Death; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000648:ultrastructure; D002478:Cells, Cultured; D053938:DNA Fragmentation; D029822:Enterovirus B, Human / Q000472:pathogenicity*; D004996:Ethidium / Q000031:analogs & derivatives / Q000378:metabolism; D005721:Glutamate-Cysteine Ligase / Q000096:biosynthesis; D005978:Glutathione / Q000032:analysis; D006801:Humans; D020287:In Situ Nick-End Labeling; D007340:Insulinoma; D007515:Islets of Langerhans / Q000473:pathology* / Q000821:virology*; D051379:Mice; D009336:Necrosis; D009573:Nitrites / Q000032:analysis
D001562:Benzimidazoles; D009573:Nitrites; C018533:ethidium homodimer; D005721:Glutamate-Cysteine Ligase; D004996:Ethidium; D005978:Glutathione; C017807:bisbenzimide ethoxide trihydrochloride